Capillary Tech.Q1 FY27
Capillary Tech. Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹510P/E: 78.0Market Cap: ₹4.0K CrSector: IT - Software
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- →Capillary Technologies expects to exceed their revenue guidance of INR1,065 crores and INR172 crores EBITDA but is not revising guidance yet.
- →New Annual Contract Value (ACV) grew about 75% YoY, indicating strong momentum in new sales across US, Europe, and Asia.
- →Organic growth guidance for FY27 is around 17%-23%, with inorganic growth supplementing this.
- →SessionM acquisition adds to revenue with server cost efficiencies improving margins; migration expected over 2-3 years.
- →Net Retention Rate (NRR) expansion and upselling new AI products contribute to higher revenues and margins.
- →Company targets combined 15%-20% organic growth with ongoing inorganic acquisitions as a sales motion.
- →Larger enterprise client wins are increasing both organically and via acquisitions.
- →AI-driven upgrades and cross-selling further fuel revenue growth and profitability.
Margin guidance
Category 3- →Capillary Technologies expects to exceed its revenue guidance of INR1,065 crores and INR172 crores EBITDA but is not revising guidance yet (Page 24).
- →Organic growth is projected at about 17% full-year, factoring in currency impact (~6%) (Page 18).
- →New ACV is seeing strong momentum with potential to deliver 30-40% more new ACV than last year (Page 23).
- →SessionM acquisition is expected to improve margins from break-even to ~15% EBITDA in one year, and 35-40% over two years through operational efficiencies (Page 23).
- →The company maintains a Rule of 40 metric of about 60 (growth + EBITDA%), with organic EBITDA margins over 20% and overall adjusted EBITDA ~17% (Page 8).
- →AI product adoption and inorganic acquisitions are key growth drivers, expected to fuel margin expansion and profitability (Pages 24, 18).
- →Normalized PAT rose from INR19 crores to INR25 crores quarter-on-quarter, indicating improving profitability (Page 8).
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
- →Aneesh Reddy discussed acquisitions and organic growth but did not reference any fundraising activities.
- →The company focuses on disciplined M&A at attractive prices and strong organic growth, implying internal funding for expansion.
- →No details on new financing rounds, debt issuance, or equity offerings were disclosed during the call.
- →The insurance policy was mentioned relating to a fraud incident, but that is unrelated to fundraising.
Order book
- →The ACV (Annual Contract Value) reported was INR 92 crores, up from INR 53 crores previously, representing about 80% growth on a trailing 12-month basis.
- →Average deal cycles are approximately 9 months, so quarter-to-quarter comparisons are less meaningful.
- →There is strong momentum in new sales across the US, Europe, and Asia.
- →Expecting at least 30%-40% more new ACV than last year, though unlikely to hit 75% growth for the full year.
- →INR 20 crores from INR 390 crores of revenue has the potential to deliver an incremental INR 120-130 crores as migrations and upgrades happen.
- →Existing inorganic revenues (like from Kognitiv) also show potential margin expansions as migrations progress.
- →No specific numeric value for pending orders disclosed, but the guidance confirms a solid pipeline with organic and inorganic growth prospects.
Capex plans
YesThe provided pages from the Capillary Technologies India Limited Q1 FY27 earnings call transcript do not explicitly mention any current or future capital expenditure (capex), capital investment, or strategic investment plans.
However, some relevant points inferred include:
- Focus on M&A strategy: The company continues to pursue inorganic growth by acquiring businesses, primarily to add long-term contracts and migrate customers to Capillary’s tech platform.
- Investments in technology: Significant investment in AI for faster and more efficient migration of acquired customers to Capillary’s platform.
- Product and platform enhancements: Continuous investment to maintain a leadership position and stay at least a year ahead of competitors in product quality.
- No direct mention of specific capex spend or strategic capital outlay figures or forecasts in the provided pages.
If you need more detailed or specific insights on capex or strategic investments, those might appear elsewhere in the full report.
How does Capillary Tech. rank vs peers in IT - Software?
Pro feature1Capillary Tech.
Rev 2Mar 3
See full IT - Software sector rankings
How does Capillary Tech. rank in IT - Software?
Compare Capillary Tech. against every IT - Software company (Q1 FY27) on revenue, margins and earnings-call signals.